Tandem Versus Single Autologous Stem Cell Transplantation for High‐Risk Multiple Myeloma in the Era of Novel Agents: A Real‐World Study of China by Xuelin Dou, Juan Ren, Jiangtao Li, Xiaodan Liu, Li Bao, Yuan Chen, Peng Zhao, Yuping Zhong, Nan Peng, Lei Wen, Leqing Cao, Yang Liu, Daoxing Deng, Fengrong Wang, Liru Wang, Hui Liu, Xiaojun Huang, Xiaodong Mo, Jin Lu

“…Conclusions Tandem ASCT demonstrated improved outcomes compared to single ASCT in high‐risk MM patients receiving triplet or quadruplet induction and maintenance therapy. However, patients with ultra high‐risk cytogenetics may require innovative therapeutic approaches, as tendem ASCT does not overcome their adverse prognosis.…”
Get full text

STAGER checklist: Standardized testing and assessment guidelines for evaluating generative artificial intelligence reliability by Jinghong Chen, Lingxuan Zhu, Weiming Mou, Anqi Lin, Dongqiang Zeng, Chang Qi, Zaoqu Liu, Aimin Jiang, Bufu Tang, Wenjie Shi, Ulf D. Kahlert, Jianguo Zhou, Shipeng Guo, Xiaofan Lu, Xu Sun, Trunghieu Ngo, Zhongji Pu, Baolei Jia, Che Ok Jeon, Yongbin He, Haiyang Wu, Shuqin Gu, Wisit Cheungpasitporn, Haojie Huang, Weipu Mao, Shixiang Wang, Xin Chen, Loïc Cabannes, Gerald Sng Gui Ren, Iain S. Whitaker, Stephen Ali, Quan Cheng, Kai Miao, Shuofeng Yuan, Peng Luo

Get full text

Noninvasive respiratory support following extubation in critically ill adults with obesity: a systematic review and network meta-analysisResearch in context by Joris Pensier, Arthur Naudet-Lasserre, Clément Monet, Mathieu Capdevila, Yassir Aarab, Inès Lakbar, Gérald Chanques, Nicolas Molinari, Audrey De Jong, Samir Jaber

“…Discrepancies were found in the results of recent randomized controlled trials (RCTs) regarding the roles of noninvasive ventilation (NIV), high flow nasal cannula (HFNC) and conventional oxygen therapy (COT) to prevent extubation failure in critically ill patients with obesity. …”
Get full text

A New CYP2E1 Inhibitor, 12-Imidazolyl-1-dodecanol, Represents a Potential Treatment for Hepatocellular Carcinoma by Torsten Diesinger, Alfred Lautwein, Sebastian Bergler, Dominik Buckert, Christian Renz, Radovan Dvorsky, Vyacheslav Buko, Siarhei Kirko, Edith Schneider, Florian Kuchenbauer, Mukesh Kumar, Cagatay Günes, Felicitas Genze, Berthold Büchele, Thomas Simmet, Martin Haslbeck, Kai Masur, Thomas Barth, Dieter Müller-Enoch, Thomas Wirth, Thomas Haehner

“…Specifically, CYP2E1 has not yet been defined as a molecular target for HCC therapy. In addition, a CYP2E1-specific drug has not been developed. …”
Get full text

Disrupting EDEM3‐induced M2‐like macrophage trafficking by glucose restriction overcomes resistance to PD‐1/PD‐L1 blockade by Shaoyong Peng, Minshan Wu, Qian Yan, Gaopo Xu, Yumo Xie, Guannan Tang, Jinxin Lin, Zixu Yuan, Xiaoxia Liang, Ze Yuan, Jingrong Weng, Liangliang Bai, Xiaolin Wang, Huichuan Yu, Meijin Huang, Yanxin Luo, Xiaoxia Liu

“…Conclusions Our study suggests that blocking EDEM3‐induced M2‐like macro phage trafficking by FMD plus 2‐DG is a promising and effective strategy to overcomeresistance to checkpoint blockade therapy offeringhope for improved treatment outcomes. …”
Get full text

NFE2-driven neutrophil polarization promotes pancreatic cancer liver metastasis progression by Wenchao Xu, Jianzhou Liu, Qiaofei Liu, Jia Xu, Li Zhou, Zhiyong Liang, Haoran Huang, Bowen Huang, Gary Guishan Xiao, Junchao Guo

“…Collectively, our data demonstrate that NFE2-driven neutrophil polarization is a potential target for anti-metastatic therapy.…”
Get full text

Superior Mesenteric Artery Syndrome: Clinical, Endoscopic, and Radiological Findings by Emanuele Sinagra, Dario Raimondo, Domenico Albano, Valentina Guarnotta, Melania Blasco, Sergio Testai, Marta Marasà, Vincenzo Mastrella, Valerio Alaimo, Valentina Bova, Giovanni Albano, Dario Sorrentino, Giovanni Tomasello, Francesco Cappello, Angelo Leone, Francesca Rossi, Massimo Galia, Roberto Lagalla, Federico Midiri, Gaetano Cristian Morreale, Georgios Amvrosiadis, Guido Martorana, Marcello Giuseppe Spampinato, Vittorio Virgilio, Massimo Midiri

“…After, a gastroenterologist and a nutritionist personalized the therapy. Furthermore, we compared the demographical, clinical, endoscopic, and radiological parameters of these cases with a control group consisting of 10 cases out of 2380 EGDS of initially suspected (but not radiologically confirmed) SMA over a follow-up 2-year period (2015-2016). …”
Get full text

Desigualdades relacionadas à participação em aulas de Educação Física entre adolescentes sul-americanos: uma análise com 173.288 participantes by Raphael Henrique de Oliveira Araujo, André Oliveira Werneck, Thiago Sousa Matias, Rafael Miranda Tassitano, Clarice Maria de Lucena Martins, Nicolas Aguilar-Farias, Gilmar Mercês de Jesus, Robinson Ramírez-Vélez, Se-Sergio Baldew, Cecilia Anza-Ramirez, Mario Germán Álvarez-Álvarez, Javier Brazo-Sayavera, Danilo Rodrigues Pereira da Silva

Get full text

“Holding on to Hope”: follow up qualitative findings of a tobacco treatment intervention for people experiencing mental health conditions by Tessa-May Zirnsak, Kristen McCarter, Melissa L. McKinlay, Ashleigh Guillaumier, Nadine Cocks, Catherine Brasier, Laura Hayes, Amanda L. Baker, Donita E. Baird, Billie Bonevski, Ron Borland, Ron Borland, David Castle, Erin Forbes, Peter J. Kelly, Catherine Segan, Catherine Segan, Rohan Sweeney, Alyna Turner, Alyna Turner, Jill M. Williams, Lisa Brophy, Lisa Brophy

“…The Quitlink study was a randomized controlled trial combining a tailored 8-week Quitline intervention delivered by dedicated Quitline counsellors plus combination nicotine replacement therapy for people who experience SMI. The purpose of this paper is to report on the medium- and longer-term findings from interviews conducted at 5 and 8 months.MethodsAs a part of the broader Quitlink study, participants were invited to qualitative interviews at 2, 5 and 8 months following recruitment, in line with quantitative follow-up time points. …”
Get full text

Mesenchymal Progenitor Cells and Their Orthopedic Applications: Forging a Path towards Clinical Trials by Deana S. Shenaq, Farbod Rastegar, Djuro Petkovic, Bing-Qiang Zhang, Bai-Cheng He, Liang Chen, Guo-Wei Zuo, Qing Luo, Qiong Shi, Eric R. Wagner, Enyi Huang, Yanhong Gao, Jian-Li Gao, Stephanie H. Kim, Ke Yang, Yang Bi, Yuxi Su, Gaohui Zhu, Jinyong Luo, Xiaoji Luo, Jiaqiang Qin, Russell R. Reid, Hue H. Luu, Rex C. Haydon, Tong-Chuan He

“…Thus, engineering such cells to maximize therapeutic potential has been the focus of cell/gene therapy to date. Here, we discuss the path towards the development of clinical trials utilizing BMSCs for orthopaedic applications. …”
Get full text

Hsp90α promotes lipogenesis by stabilizing FASN and promoting FASN transcription via LXRα in hepatocellular carcinoma by Zihao Deng, Lixia Liu, Guantai Xie, Zhenming Zheng, Jieyou Li, Wenchong Tan, Yaotang Deng, Jinxin Zhang, Manfeng Liang, Yingxia Wu, Zhifeng Zhou, Yan Li, Yukui Chen, Yaling Huang, Hairou Su, Guibing Wu, Xiongjie Shi, Shengpei Cen, Yandan Liao, Yilin Liu, Fei Zou, Xuemei Chen

“…Our data reveal that Hsp90α promotes lipid accumulation by increasing the protein stability and FASN mRNA transcription, and can be alleviated by Hsp90 inhibitors, which provides a theoretical basis for Hsp90-targeted therapy on lipid metabolism in HCC.…”
Get full text

MAM‐STAT3‐Driven Mitochondrial Ca+2 Upregulation Contributes to Immunosenescence in Type A Mandibuloacral Dysplasia Patients by Arshad Ahmed Padhiar, Xiaohong Yang, Syed Aqib Ali Zaidi, Zhu Li, Jinqi Liao, Wei Shu, Arif Ali Chishti, Liangge He, Gulzar Alam, Abdullah Faqeer, Ilyas Ali, Shuai Zhang, Ting Wang, Tao Liu, Meiling Zhou, Gang Wang, Yan Zhou, Guangqian Zhou

“…These results provide new insights into MAD disease and propose targeting defective mitochondrial Ca+2 homeostasis as a promising therapy for reversing immunosenescence.…”
Get full text

Trifluridine-tipiracil in previously treated patients with oestrogen receptor-positive, HER2-negative metastatic breast cancer (BOOG 2019-01 TIBET trial): a single-arm, multicentre... by Niels A.D. Guchelaar, Ron H.J. Mathijssen, Maaike de Boer, Marlies L. van Bekkum, Joan B. Heijns, Birgit E.P.J. Vriens, Mandy M. van Rosmalen, Lonneke W. Kessels, Lisanne Hamming, Karin J. Beelen, Peter Nieboer, Susan M. van den Berg, Esther Oomen-de Hoop, Rhodé M. Bijlsma, Monique E.M.M. Bos

“…Findings: Fifty female patients were enrolled from September 2020 to July 2023, with a median of 3 (IQR, 2–3) previous endocrine therapy lines and 2 (IQR, 2–3) chemotherapy lines for MBC. …”
Get full text

Clinical and experimental rationale for using phenylephrine with hypromellose for the treatment of extra accommodation strain in patients with myopia by M.V. Makhova, E.V. Shikh, V.V. Strakhov, D.S. Blinov, G.K. Poluosmak, E.V. Semeleva, E.V. Blinova

“…</p> <p> <b>Results</b>: the drug therapy of extra accommodation strain comprising 2.5% phenylephrine hydrochloride solution with hypromellose as an excipient (Irifrin^® BK) demonstrated a decrease in severity of extra accommodation strain after 30 days of treatment. …”
Get full text

Decreased risk of cardiovascular disease mortality associated with occasional positive screens following cancer screenings by Yuting Ji, Yu Zhang, Hongyuan Duan, Xiaomin Liu, Yunmeng Zhang, Zhuowei Feng, Jingjing Li, Zeyu Fan, Ya Liu, Yacong Zhang, Lei Yang, Zhangyan Lyu, Fangfang Song, Fengju Song, Hua Li, Yubei Huang

Get full text

The effect of the number of endometrial CD138+ cells on the pregnancy outcomes of infertile patients in the proliferative phase by Yuye Li, Yuye Li, Shuyi Yu, Shuyi Yu, Wenjuan Liu, Yawen Chen, Xiaobing Yang, Juanhua Wu, Mingjuan Xu, Guanying You, Ruochun Lian, Chunyu Huang, Chunyu Huang, Wanru Chen, Yong Zeng, Yong Zeng, Fenghua Liu, Lianghui Diao

“…The number of CD138+ cells was compared in the proliferative and mid-luteal phases of the same patients without antibiotic therapy. Infertile patients were separated into three groups based on the number of positive lesions [the number of high power fields (HPFs) containing no less than five CD138+ cells]: 0 (n = 474), 1-2 (n = 125), and ≥3 positive lesions (n = 104). …”
Get full text

Therapeutic benefit of the dual ALK/FAK inhibitor ESK440 in ALK-driven neuroblastoma by Seema Chugh, Jean C. Tien, Jennifer Hon, Carson Kenum, Rahul Mannan, Yunhui Cheng, Chi Chiang Li, Zainab I. Taher, Andrew D. Delekta, Pushpinder Singh Bawa, Ingrid J. Apel, Stephanie J. Miner, Xuhong Cao, Rohit Mehra, Saravana M. Dhanasekaran, Yuanyuan Qiao, Rajen Mody, Arul M. Chinnaiyan

“…More than half of patients have metastases detected at diagnosis, and high-risk disease is associated with five-year survival rates of only 50–60 %. Standard therapy involves highly toxic chemotherapy, surgery, radiation, and immunotherapy, and less toxic, more specific targeted therapies are urgently needed. …”
Get full text

Generation of a USP9Y knockout human embryonic stem cell line with CRISPR-Cas9 technology by Sai Wei, Yuting Zhen, Chao Sun, Yanlin Ma, Qi Li, Luan Wen

“…Human embryonic stem cell (hESC) lines are vital tools for studying gene function, disease modeling, and therapy. We generated a USP9Y knockout hESC line using CRISPR-Cas9 in the male-derived H1 line. …”
Get full text

FGF21 ameliorates diabetic nephropathy through CDK1-dependently regulating the cell cycle by Yudie Zhang, Yudie Zhang, Yudie Zhang, Yudie Zhang, Yudie Zhang, Fan Wang, Fan Wang, Fan Wang, Fan Wang, Chongyang Zhang, Chongyang Zhang, Chongyang Zhang, Chongyang Zhang, Fan Yao, Fan Yao, Fan Yao, Fan Yao, Bin Zhang, Bin Zhang, Bin Zhang, Bin Zhang, Yongping Zhang, Xiaobo Sun, Xiaobo Sun, Xiaobo Sun, Xiaobo Sun

“…Furthermore, we used db/db mice and FGF21 direct therapy for 8 weeks to investigate changes in fasting glucose and creatinine expression as well as pathological changes in glomeruli glycogen deposition, fibrosis, and nephrin expression. …”
Get full text

Evaluation of S100A8/A9 and neutrophils as prognostic markers in metastatic melanoma patients under immune-checkpoint inhibition by Yasmin F Melzer, Nadine L Fergen, Christian Mess, Julia-Christina Stadler, Glenn Geidel, Ysabel A Schwietzer, Julian Kött, Klaus Pantel, Stefan W Schneider, Jochen Utikal, Ewa Wladykowski, Sabine Vidal-y-Sy, Alexander T Bauer, Christoffer Gebhardt

“…Immune-checkpoint inhibitors (ICIs) have revolutionized melanoma treatment, yet approximately half of patients do not respond to these therapies. Identifying prognostic biomarkers is crucial for treatment decisions. …”
Get full text